ASTH three-lens brief
Evidence-based stock research on ASTH. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Moved +2.36% yesterday. · Trading >3% below the 50-day MA — short-term weakness.
- Moved +2.36% yesterday.
- Trading >3% below the 50-day MA — short-term weakness.
- Analyst mean target $51.89 — 58% above current (9 analysts).
- Reported earnings on 2026-11-05.
ASTH closed at $32.94 (+2.36%) as of 2026-11-12. Market cap: $1.64B. P/E (trailing) 30.5. Price is below the 50-day MA and below the 200-day MA. Positives: moved +2.36% yesterday.; analyst mean target $51.89 — 58% above current (9 analysts).. Concerns: trading >3% below the 50-day MA — short-term weakness.. Last quarter: Revenue $1.02B, net income $12.95M, free cash flow $99.12M.
Why three lenses on ASTH, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ASTH across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/ASTH" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ASTH brief"></iframe>